Cognitive Enhancers

Nootropic

The use of cognition-enhancing drugs by healthy individuals in the absence of a medical indication is one of the most debated topics among neuroscientists, psychiatrists, and physicians who spans a number of issues, including the ethics and fairness of Their use, concerns over adverse effects, and the diversion of prescription drugs for nonmedical uses, among others. Nonetheless, the international sales …

Nootropic Read More »

Dextroamphetamine

The Dextroamphetamine is a psychostimulant drug. It is a non- catecholamine sympathomimetic amine which is the dextrorotatory stereoisomer of the amphetamine molecule . The amphetamine molecule has another stereoisomer: levoamphetamine . Dextroamphetamine is available as a generic drug or under several brands. Dextroamphetamine is often mistakenly called amphetamine, as if it were a synonym, however, …

Dextroamphetamine Read More »

Altinicline

Altinicline (SIB-1508Y, SIB-1765F) is a drug that acts as an agonist in nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. [2] It stimulates the release of dopamine and acetylcholine in the brain in both rodent and primate models, [3] and progressed to Phase II clinical trials for Parkinson’s disease , [4] where “non-antiparkinsonian …

Altinicline Read More »

Unifiram

Unifiram is an ampakine drug that acts as a positive allosteric modulator of the AMPA receptor , 1 which has been shown to have nootropic effects in animals. 2 3 A series of related compounds are known, one being the sunifiram (DM-235). 4 5 6 This drug has two enantiomers , with (R) – (+) …

Unifiram Read More »

Adderall

Adderall is a combined drug containing salts of the two enantiomers of amphetamine, a central nervous system (CNS) stimulant of the phenethylamine class. Adderall is used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. It is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and …

Adderall Read More »

NNI-351

NNI-351 is an active oral inhibitor of DYRK1A and a neurogenesis enhancer that is being developed by NeuroNascent, Inc. for the treatment of Down syndrome, depression and post-traumatic stress disorder (PTSD). [1] [2] Beginning in 2017, it is in the preclinical development phase and has not yet progressed in human clinical trials

CREB in cognition

The cell transcription factor CREB (cAMP response element binding protein) [1] helps in the learning and stabilization and recovery of long-term memories based on fear. This is mainly due to its expression in the hippocampus and amygdala. Studies that support the role of CREB in cognition include those that eliminate the gene, reduce expression, or …

CREB in cognition Read More »

what are nootropic

The nootropics (from nous mind and tropos bend) or nootropics are drugs , the drugs , plants and various substances having an action of modulation of physiology and psychology involving cognitive increase and that no or relatively little effect Health hazards at standard doses. Nootropics are promoted in transhumanism as a general means of improving living conditions, or for specific purposes, such as increased motivation. Since the year 2000, more substances (eg, rivastigmine , the galantamine or aniracetam) are …

what are nootropic Read More »

Basmisanil

Basmisanil (INN) (developmental code names RG-1662, RO5186582) is a highly selective inverse agonist / negative allosteric modulator of GABA A receptors containing an α 5 subunit developed by Roche for the treatment of cognitive impairments associated with the syndrome Of Down. In August 2015, these are Phase II clinical trials for this indication.